secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0000950170-22-017382
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Equillium Q2 net loss $14.1M (-$0.41/sh); cash $57.6M; clinical pipeline on track
--------------------------------------------------------------------------------

- Net loss $14.1M, or $(0.41) per share, vs $9.2M ($0.31) in Q2 2021; R&D spend $9.5M.
- Cash, cash equivalents and short-term investments $57.6M as of June 30, 2022.
- Phase 3 EQUATOR study of itolizumab in aGVHD continues enrollment; interim data from lupus nephritis study expected mid-2022.
- Phase 2 study of EQ101 in alopecia areata and Phase 1 study of EQ102 in celiac disease expected to initiate 2H 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000095017022017382/0000950170-22-017382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000095017022017382/eq-20220815.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-017382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer